Modified prescription-event monitoring studies: A tool for pharmacovigilance and risk management

Drug Safety

Volumn 34, Issue 12, 2011, Pages

  Layton, Deborah ^a,b   Hazell, Lorna ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Adverse reaction monitoring; Pharmacoepidemiology; Postmarketing surveillance; Prescription event monitoring

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTIASTHMATIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATOMOXETINE; CARVEDILOL; CYCLOOXYGENASE 2 INHIBITOR; DROSPIRENONE PLUS ETHINYLESTRADIOL; FENTANYL; FENTANYL CITRATE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; IVABRADINE; MODAFINIL; NEUROLEPTIC AGENT; QUETIAPINE; RIMONABANT; SEROQUEL XL; TRAVOPROST; UNCLASSIFIED DRUG; VARENICLINE;

AGGRESSION; ANXIETY; ARTICLE; AUTOMUTILATION; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DEEP VEIN THROMBOSIS; DEPRESSION; DIABETES MELLITUS; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EXTRAPYRAMIDAL SYNDROME; EYE DISEASE; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MENTAL DISEASE; METABOLIC SYNDROME X; METERED DOSE INHALER; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; RISK MANAGEMENT; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SUICIDAL IDEATION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

COHORT STUDIES; DRUG UTILIZATION; FAMILY PRACTICE; GREAT BRITAIN; HUMANS; PRESCRIPTION DRUGS; PRODUCT SURVEILLANCE, POSTMARKETING; QUESTIONNAIRES;

EID: 81055147682     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11593830-000000000-00000     Document Type: Article

References (30)

1. Shakir SAW. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley & Sons Ltd, 2007: 307-16
2. Clark D, Harrison-Woolrych M. The role of the New Zealand IntensiveMedicinesMonitoring Programme in identification of previously unrecognised signals of adverse drug reactions. Curr Drug Saf 2006; 1 (2): 169-78
3. Kubota K. Prescription-event monitoring in Japan (J-PEM). Drug Saf 2002; 25 (6): 441-4 (Pubitemid 34729143)
4. Dodoo AN, Fogg C, Asiimwe A, et al. Pattern of drug utilization for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinin-combination therapy. Malaria J 2009; 8: 2
5. Boshier A, Wilton LV, Shakir SAW. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int 2004; 93: 796-801 (Pubitemid 38497030)
6. Hazell L, Cornelius V, Wilton L, et al. The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16, 129 patients. BJU International 2009; 103: 506-14
7. Pearce HM, Layton D, Wilton LV, et al. Deep vein thrombosis and pulmonary embolismreported in the prescriptionevent monitoring study of Yasmin. Br J Clin Pharmacol 2005; 60 (1): 98-102 (Pubitemid 40942787)
8. Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf 2006; 29 (8): 687-96 (Pubitemid 44175039)
9. The National Information Governance Board. Register of approved section 251 applications [online]. Available from URL: http://www.nigb.nhs.uk/ecc/reg. [Accessed 2010 Sep 3]
10. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs.AmJ Epidemiol 2003; 158 (9): 915-20 (Pubitemid 37323253)
11. Leufkens HG, Urquhart J, Stricker BH, et al. Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems. J Epidemiol Community Health 1992 Aug; 46 (4): 428-32
12. Layton D, Souverein PC, Heerdink ER, et al. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in non-selective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands. Drug Saf 2008; 31 (2): 143-58 (Pubitemid 351158525)
13. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-7 (Pubitemid 24236255)
14. Groves RM, Peytcheva E. The impact of nonresponse rates on nonresponse bias: a meta-analysis. Public Opin Q 2008; 72: 167-89
15. Cummings P, McKnight B, Greenland S. Matched cohort methods for injury research. Epidemiol Rev 2003; 25: 43-50 (Pubitemid 36944550)
16. Whitaker HJ, Hocine M, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res 2009; 18 (1): 7-26
17. Strom B. Sample size considerations for pharmacoepidemiology studies. In: Strom B, editor. Pharmacoepidemiology. 4th ed. Chichester: JohnWiley & Sons Ltd, 2005: 29-36
18. European Commission. Volume 9A. Pharmacovigilance for medicinal products for human use. September 2008 [online]. Available from URL: http://ec.europa.eu/ health/files/eudralex/vol-9/pdf/vol9a-09-2008-en.pdf [Accessed 2009 Apr 7]
19. Aurich-Barrera B, Wilton LV, Shakir SA. Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study. Drug Saf 2009; 32 (1): 43-54
20. Perrio M, Wilton LV, Shakir SAW. A modified prescription-event monitoring study to assess the introduction of flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring. Pharmacoepidemiol Drug Saf 2007; 16: 969-78 (Pubitemid 47422845)
21. Perrio M, Wilton LV, Shakir SAW. A modified prescription-event monitoring study to assess the introduction of seretide Evohalerin England: an example of studying risk monitoring in pharmacovigilance. Drug Saf 2007; 30 (8): 681-95 (Pubitemid 47295828)
22. Davies MN, Paiba N, Wilton LV, et al. A 12-month modified prescription-event monitoring report for travoprost [abstract no. P.020]. 7th Annual Conference of ISOP. 2007 Oct 21-24;
23. Bournemouth. Drug Saf 2007; 30 (10): 919-90
24. Davies MN, Wilton LV, Shakir SAW. Safety profile ofmodafinil used in general practice in England: a modified prescriptionevent monitoring study [abstract]. Drug Saf 2008; 31 (10): 892
25. Buggy Y, Cornelius V, Wilton L, et al. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf 2011; 34 (6): 501-9
26. Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009; 32 (6): 499-507
27. Food and Drug Administration. FDA issues public health advisory on Strattera (atomoxetine) for attention deficit disorder [online]. Available from URL: http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108493. htm [Accessed 2011 Apr 17]
28. European Medicines Agency. Procoralan-(ivabradine). European public assessment report. London: European Medicines Agency, 2005
29. Cephalon Europe. Effentora-buccal tablets: summary of product characteristics. Cephalon, 2008 [online]. Available from URL: http://www.medicines.org.uk/emc/medicine/21401 [Accessed 2011 Sep 8]
30. Astra Zeneca UK. Seroquel XL tablets: summary of product characteristics. AstraZeneca, 2008 [online]. Available from URL: http://www.medicines.org.uk/ emc/medicine/21175 [Accessed 2011 Sep 8]